| Literature DB >> 22649299 |
Hamid Abdi1, Baixiao Zhao, Mahsa Darbandi, Majid Ghayour-Mobarhan, Shima Tavallaie, Amir Ali Rahsepar, Seyyed Mohammad Reza Parizadeh, Mohammad Safariyan, Mohsen Nemati, Maryam Mohammadi, Parisa Abbasi-Parizad, Sara Darbandi, Saeed Akhlaghi, Gordon A A Ferns.
Abstract
A randomized controlled clinical trial in 196 obese subjects was performed to examine the effectiveness of body acupuncture on body weight loss, lipid profile and immunogenic and inflammatory markers. Subjects received authentic (cases) or sham (controls) acupuncture for 6 weeks in combination with a low-calorie diet. In the following 6 weeks, they received the low-calorie diet alone. Subjects were assessed at the beginning, 6 and 12 weeks later. Heat shock protein (Hsps)-27, 60, 65, 70 antibody titers and high sensitivity C-reactive protein (hs-CRP) levels were also assessed. A significant reduction in measures of adiposity and improvement in lipid profile were observed in both groups, but the levels of anti-Hsp-antibodies decreased in cases only. A reduction in anthropometric and lipid profile in cases were sustained in the second period, however, only changes in lipid profile were observed in the control group. Anti-Hsp-antibodies and hs-CRP levels continued to be reduced in cases but in controls only the reduction in hs-CRP remained. Changes in anthropometric parameters, lipid profile, and anti-Hsp-antibodies were more evident in cases. Body acupuncture in combination with diet restriction was effective in enhancing weight loss and improving dyslipidemia.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22649299 PMCID: PMC3353309 DOI: 10.1100/2012/603539
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Trial profile and design.
Comparison between clinical and biochemical characteristics of participants.
| Group | Real ( | Sham ( |
|---|---|---|
| Age (year) | 36.88 ± 0.98 | 37.41 ± 1.01 |
| Weight (kg) | 84.10 ± 1.67 | 85.02 ± 1.75 |
| Height (cm) | 161.08 ± 0.83 | 160.79 ± 0.92 |
| Body fat (%) | 37.00 ± 0.69 | 37.08 ± 0.79 |
| BMI (Kg/m2) | 32.30 ± 0.52 | 32.74 ± 0.59 |
| WC (cm) | 102.39 ± 1.28 | 100.74 ± 1.36 |
| HC (cm) | 113.76 ± 1.03 | 114.98 ± 1.18 |
| WC/HC ratio | 0.90 ± 0.1 | 0.87 ± 0.008 |
| FBS (mg/dL) | 84.48 ± 1.46 | 87.76 ± 2.58 |
| TC (mg/dL) | 173.54 ± 4.13 | 171.96 ± 4.11 |
| TG (mg/dL) | 112.48 ± 6.24 | 123.58 ± 5.8 |
| HDL-C (mg/dL) | 42.60 ± 0.99 | 41.65 ± 1.06 |
| LDL-C (mg/dL) | 108.19 ± 3.44 | 107.46 ± 3.05 |
| DBP (mmHg) | 73.33 ± 1.71 | 75.95 ± 1.67 |
| SBP (mmHg) | 107.91 ± 1.92 | 107.38 ± 1.77 |
| Anti-HSP27 antibody | 0.37 (0.32–0.41) | 0.35 (0.33–0.41) |
| Anti-HSP60 antibody | 0.74 (0.68–0.86) | 0.72 (0.69–0.78) |
| Anti-HSP65 antibody | 0.81 (0.73–0.90) | 0.81 (0.78–0.83) |
| Anti-HSP70 antibody | 0.59 (0.55–0.67) | 0.61 (0.57–0.66) |
| hs-CRP (mg/dL) | 1.78 (1.15–3.06) | 1.79 (0.99–3.39) |
BMI: body mass index; WC: waist circumference; HC: hip circumference; FBS: fasting blood sugar; TC: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol, DBP: diastolic blood pressure, SBP: systolic blood pressure, Anti-Hsp antibody: Anti-heat shock protein, hs-CRP: high-sensitivity C-reactive protein. Values are expressed as mean ± SEM, or median and interquartile range. Chi-square test (for qualitative variable), independent sample t-test (for normally distributed data), and Mann-Whitney test (for non-normally distributed data) were used for comparison 2 groups.
Comparison of clinical and biochemical characteristics of participants of body group.
| Variable | Real group | Sham group | ||||
|---|---|---|---|---|---|---|
| 1st sample | 2nd sample | 3rd sample | 1st sample | 2nd sample | 3rd sample | |
| Weight (kg) | 84.10 ± 1.67 | 81.23 ± 1.68 | 81.27 ± 2.41 | 85.02 ± 1.75 | 82.81 ± 1.81 | 84.96 ± 2.56 |
| Body fat (%) | 37.00 ± 0.69 | 36.03 ± 0.7 | 37.91 ± 1.91 | 37.08 ± 0.79 | 36.54 ± 0.84 | 36.35 ± 1.01 |
| BMI (Kg/m2) | 32.30 ± 0.52 | 31.17 ± 0.53 | 30.98 ± 0.62 | 32.74 ± 0.59 | 31.87 ± 0.61 | 31.73 ± 0.74 |
| WC (cm) | 102.39 ± 1.28 | 95.12 ± 1.2 | 92.90 ± 1.43 | 100.74 ± 1.36 | 96.66 ± 1.26 | 97.16 ± 1.31 |
| HC (cm) | 113.76 ± 1.03 | 106.59 ± 0.93 | 105.84 ± 1.19 | 114.98 ± 1.18 | 111.10 ± 1.15 | 110.40 ± 1.48 |
| WC/HC ratio | 0.90 ± 0.1 | 0.89 ± 0.01 | 0.087 ± 0.01 | 0.87 ± 0.008 | 0.87 ± 0.007 | 0.88 ± 0.008 |
| FBS (mg/dL) | 84.48 ± 1.46 | 87.46 ± 1.33 | 87.27 ± 3.1 | 87.76 ± 2.58 | 89.64 ± 3.40 | 90.03 ± 3.37 |
| TC (mg/dL) | 173.54 ± 4.13 | 148.18 ± 3.92 | 137.98 ± 3.71 | 171.96 ± 4.11 | 162.23 ± 3.72 | 157.15 ± 3.82 |
| TG (mg/dL) | 112.48 ± 6.24 | 92.51 ± 4.40 | 87.69 ± 4.55 | 123.58 ± 5.8 | 122.97 ± 5.68 | 108.76 ± 6.37 |
| HDL-C (mg/dL) | 42.60 ± 0.99 | 38.51 ± 0.88 | 54.33 ± 2.96 | 41.65 ± 1.06 | 38.16 ± 0.94 | 53.05 ± 3.01 |
| LDL-C (mg/dL) | 108.19 ± 3.44 | 91.34 ± 3.48 | 74.50 ± 3.60 | 107.46 ± 3.05 | 99.92 ± 2.89 | 93.27 ± 3.12 |
| Anti-HSP27 | 0.37 (0.32–0.41) | 0.33 (0.29–0.37) | 0.31 (0.28–0.34) | 0.35 (0.33–0.41) | 0.36 (0.32–0.39) | 0.36 (0.33–0.41) |
| Anti-HSP60 | 0.74 (0.68–0.86) | 0.73 (0.62–0.80) | 0.70 (0.62–0.77) | 0.72 (0.69–0.78) | 0.73 (0.68–0.78) | 0.73 (0.67–0.78) |
| Anti-HSP65 | 0.81 (0.73–0.90) | 0.80 (0.73–0.86) | 0.77 (0.70–0.83) | 0.81 (0.78–0.83) | 0.80 (0.77–0.84) | 0.80 (0.77–0.84) |
| Anti-HSP70 | 0.59 (0.55–0.67) | 0.56 (0.52–0.64) | 0.54 (0.50–0.60) | 0.61 (0.57–0.66) | 0.60 (0.57–0.65) | 0.61 (0.56–0.66) |
| hs-CRP (mg/dL) | 1.78 (1.15–3.06) | 1.3 (1.3–3.0) | 0.8 (0.23–1.4) | 1.79 (0.99–3.39) | 1.3 (1.3–3.2) | 1.10 (0.33–2.00) |
R: Real; S: Sham; BMI: Body mass index; WC: waist circumference; HC: Hip circumference; FBS: Fasting blood sugar; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; DBP: diastolic blood pressure; SBP: systolic blood pressure. Values are expressed as mean ± SEM, or median and interquartile range. means significant changes in comparison with first sample and means significant changes in comparison with second sample.
Comparison of changes in clinical and biochemical characteristics of body acupuncture.
| Variable | Real group | Sham group | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 1st period | 2nd period | Whole period |
| 1st period | 2nd period | Whole period |
|
| |
| 1st | |||||||||
| Weight (kg) | 2.98 ± 0.22 | 1.22 ± 0.18 | 4.15 ± 0.37 | 0.000 | 2.21 ± 0.23 | 0.29 ± 0.29 | 2.40 ± 0.60 | 0.001 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| Body fat (%) | 0.90 ± 0.18 | −1.39 ± 1.72 | −0.38 ± 1.70 | 0.177 | 0.77 ± 0.20 | 0.43 ± 0.40 | 1.22 ± 0.35 | 0.507 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| BMI (Kg/m2) | 1.16 ± 0.09 | 0.29 ± 0.10 | 1.47 ± 0.14 | 0.000 | 0.86 ± 0.10 | 0.47 ± 0.27 | 1.24 ± 0.16 | 0.221 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| WC (cm) | 7.05 ± 0.60 | 1.76 ± 0.40 | 8.93 ± 0.79 | 0.000 | 4.07 ± 0.52 | −0.50 ± 0.93 | 3.97 ± 0.92 | 0.000 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| HC (cm) | 7.16 ± 0.40 | 1.63 ± 0.37 | 8.70 ± 0.56 | 0.000 | 3.76 ± 0.56 | 1.17 ± 0.68 | 5.49 ± 0.64 | 0.011 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| WC/HC ratio | 0.007 ± 0.006 | 0.003 ± 0.004 | 0.015 ± 0.008 | 0.384 | 0.006 ± 0.005 | −0.01 ± 0.008 | −0.005 ± 0.008 | 0.106 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| FBS (mg/dL) | −2.70 ± 1.39 | −0.70 ± 3.43 | −3.61 ± 2.98 | 0.611 | −2.08 ± 1.74 | 2.83 ± 2.03 | 0.45 ± 1.58 | 0.170 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| TC (mg/dL) | 25.35 ± 2.60 | 7.52 ± 2.99 | 32.62 ± 3.59 | 0.000 | 10.98 ± 3.58 | 6.80 ± 3.44 | 18.51 ± 4.46 | 0.456 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| TG (mg/dL) | 19.97 ± 3.55 | 5.73 ± 2.52 | 25.97 ± 5.53 | 0.003 | 1.48 ± 5.85 | 17.19 ± 6.84 | 21.82 ± 7.57 | 0.530 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| HDL-C (mg/dL) | 4.02 ± 0.97 | −16.07 ± 2.88 | −12.12 ± 3.12 | 0.000 | 3.97 ± 0.99 | −13.15 ± 2.80 | −10.64 ± 3.11 | 0.000 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| LDL-C (mg/dL) | 17.17 ± 2.23 | 15.19 ± 2.96 | 31.85 ± 3.13 | 0.734 | 9.03 ± 2.55 | 7.22 ± 2.80 | 15.34 ± 3.29 | 0.581 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| Anti-HSP27 Antibody | 0.03 (0.01–0.06) | 0.02 (0.0–0.04) | 0.05 (0.02–0.08) | 0.083 | 0.01 (−0.01–0.02) | −0.01 (−0.02–0.01) | 0.0 (−0.01–0.02) | 0.028 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| Anti-HSP60 Antibody | 0.03 (0.02–0.05) | 0.02 (0.01–0.05) | 0.06 (0.04–0.09) | 0.114 | 0.01 (−0.007–0.02) | 0.0 (−0.01–0.02) | 0.01 (−0.01–0.02) | 0.264 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| Anti-HSP65 Antibody | 0.02 (−0.01–0.05) | 0.03 (0.01–0.05) | 0.05 (0.03–0.08) | 0.370 | 0.01 (−0.01–0.02) | 0.005 (−0.01–0.017) | 0.01 (−0.01–0.02) | 0.569 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| Anti-HSP70 Antibody | 0.02 (0.01–0.04) | 0.02 (0.01–0.04) | 0.05 (0.03–0.07) | 0.936 | 0.01 (−0.01–0.02) | −0.005 (−0.02–0.01) | 0.0 (−0.01–0.02) | 0.096 | 2nd |
| 3rd | |||||||||
| 1st | |||||||||
| hs-CRP (mg/dL) | 0.0 (−0.63–0.94) | 0.90 (0.15–1.7) | 1.06 (0.18–1.47) | 0.024 | 0.0 (−0.58–0.75) | 0.8 (0.1–1.60) | 0.62 (0.13–1.39) | 0.226 | 2nd |
| 3rd | |||||||||
R: real; S: sham; BMI: body mass index; WC: waist circumference; HC: hip circumference; FBS: fasting blood sugar; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol, DBP: diastolic blood pressure, SBP: systolic blood pressure. Values are expressed as mean ± SEM, or median and interquartile range. Paired t-test and Wilcoxon signed ranked test were used for comparison between first and second periods for normally and nonnormally distributed data, respectively. Independent sample t-test (for normally distributed data) and Mann-Whitney test (for non-normally distributed data) were used for comparison 2 groups.
Figure 2Changes of anthropometric parameters and lipid profile in real and sham groups. BMI: body mass index, BF%: body fat percentage, WC: waist circumferences, HC: hip circumferences, TC: total cholesterol, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, TG: triglycerides. (a), (b) and (c) means first, second and whole period of the study, respectively, *P < 0.05, **P < 0.01, and ***P < 0.001, respectively.